Ixekizumab (Taltz) for adults with plaque psoriasis who are able to have systemic treatment

In 2017, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) assessed the advantages and disadvantages of ixekizumab (trade name: Taltz) for people with moderate to severe plaque psoriasis who are able to have systemic treatment. For the purpose of this comparison, the manufacturer provided data from 83 patients. Of these, 40 people had treatment with ixekizumab, while 43 had the standard treatment with fumaric acid esters.

What are the advantages of ixekizumab?

Complete remission of psoriasis: The study suggests that ixekizumab has an advantage here when compared with fumaric acid esters. About 60 out of 100 people who used ixekizumab no longer had symptoms at the end of the study. This was the case for about 2 out of 100 people who had treatment with fumaric acid esters.

The study suggested that it had further advantages in the following aspects. But, based on the data provided, it wasn't possible to estimate how big these advantages were compared to the standard treatment.

  • No visible symptoms on face and neck
  • Improvement of painful areas of skin
  • Health-related quality of life
  • Treatment stopped due to side effects

What are the disadvantages of ixekizumab?

Ixekizumab wasn't found to have any disadvantages compared with the standard treatment.

No difference

Visible symptoms in the genital area: There was no difference between the treatments here either.

What remains unanswered?

The manufacturer didn't provide any suitable data concerning the effects of treatment on nail psoriasis, general health, and severe side effects.

Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Ixekizumab (Plaque Psoriasis) – Addendum to Commission A17-07. Commission A17-30. July 28, 2017. (IQWiG reports; Volume 528).

IQWiG health information is written with the aim of helping people understand the advantages and disadvantages of the main treatment options and health care services.

Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. informedhealth.org can provide support for talks with doctors and other medical professionals, but cannot replace them. We do not offer individual consultations.

Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.

Comment on this page

What would you like to share with us?

We welcome any feedback and ideas. We will review, but not publish, your ratings and comments. Your information will of course be treated confidentially. Fields marked with an asterisk (*) are required fields.

Please note that we do not provide individual advice on matters of health. You can read about where to find help and support in Germany in our information “How can I find self-help groups and information centers?

Updated on June 28, 2018
Next planned update: 2021

Publisher:

Institute for Quality and Efficiency in Health Care (IQWiG, Germany)

How we keep you informed

Follow us on Twitter or subscribe to our newsletter or newsfeed. You can find all of our films online on YouTube.